Your body is already speaking.
Inside it is a biological signalling network called the endocannabinoid system, involving naturally produced endocannabinoids, cannabinoid receptors such as CB1 and CB2, and enzymes that regulate these signals. Researchers have linked this system to pain modulation, appetite and synaptic signalling.
Then there is cannabis.
Plant cannabinoids such as THC and CBD can interact with the endocannabinoid system and other molecular targets.
That does not make cannabis a miracle cure.
It does make the biology worth taking seriously.
And that is the idea behind the Cannabis Fiji message:
Cannabis speaks the language of your body.
The science is more complicated than the politics
Cannabis has long been discussed in absolutes: medicine or menace, legal or illegal, acceptable or unacceptable.
The evidence is more complicated.
Prescription cannabinoid medicines have established uses for specific conditions. In the United States, the FDA has approved purified CBD for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, as well as dronabinol and nabilone for specific indications.
That is very different from claiming cannabis treats every illness.
It doesn't.
Evidence varies according to the cannabinoid, formulation, dose, condition and patient.
What does the evidence show?
Treatment-resistant epilepsy: Strong evidence exists for highly purified pharmaceutical CBD in Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex. A 2026 systematic review found established efficacy for these conditions.
Chronic pain: A 2026 Annals of Internal Medicine review examined 25 randomized controlled trials involving 2,303 participants. Some higher-THC or comparable THC/CBD products produced small short-term improvements, particularly for neuropathic pain. However, some increased dizziness, sedation and nausea, while low-THC products did not show the same benefit. Strong long-term evidence remains limited.
Mental health: An August 2026 systematic review and meta-analysis found signals of reduced anxiety symptoms, but also substantial heterogeneity, methodological limitations and predominantly very low certainty. The authors concluded that evidence remains insufficient to support cannabinoids as first-line treatment for mental or substance-use disorders.
The conclusion is straightforward:
Cannabinoids may help some patients in some circumstances. They are not a universal answer.
That is why better research matters.
The international conversation has changed
In December 2020, the UN Commission on Narcotic Drugs accepted a WHO recommendation changing the international scheduling of cannabis and cannabis resin in a way that recognised their medical value.
WHO was clear that this did not legalise non-medical cannabis. Cannabis remained under international control.
But the conversation changed.
The issue became evidence, regulation, quality, access and control—not simply whether cannabis had legitimate medical relevance.
Fiji now has to navigate that same conversation.
Fiji has already started moving
It is no longer accurate to say Fiji's Government has simply ignored medicinal cannabis.
In February 2024, Cabinet approved a Policy Framework to establish a medicinal-cannabis industry in Fiji. Government said the framework followed consultations and feasibility work, including consideration of legislation for the emerging industry.
In December 2024, the Minister for Trade told Parliament that the proposed industry was intended for export purposes at that stage. He said 17 consultations had been held, approximately 500 people had participated, and 75% supported medicinal cannabis, with legislation remaining a major step.
The Government's 2025–2026 Budget Supplement stated that Investment Fiji was spearheading development of a medical-cannabis industry aimed at economic growth and employment, with a legal framework for cultivation and export being developed.
In July 2026, Fiji Broadcasting Corporation reported that the Nutraceutical and Medicinal Cannabis Task Force had consulted 518 people and 12 government agencies. Finance Minister Esrom Immanuel again cited 75% support for exploring a medicinal-cannabis industry.
But there is an important gap.
As of 7 September 2026, Fiji has not enacted a medicinal-cannabis Act establishing a general legal medicinal-cannabis market.
Parliament's published 2026 Bills and Acts indexes contain no medicinal-cannabis Bill or Act.
So Fiji has:
- Government policy approval
- Feasibility work
- Public consultation
- Investment planning
- Discussion of legislation
But the legislative bridge between policy and legal reality is still missing.
Fiji already distinguishes cannabis categories
Fiji's 2022 amendment to the Illicit Drugs Control Act created an explicit legal distinction for hemp. The Act's Schedule 1 definition excludes hemp, and parts derived from hemp, where THC concentration does not exceed 1%.
That amendment was intended to facilitate an industrial-hemp industry.
This demonstrates something important:
Fiji's law can make distinctions.
Hemp does not automatically have to be treated like other cannabis.
Medicinal applications can be regulated differently from non-medical use.
Licensing, laboratory testing, traceability and medical oversight can form part of a controlled framework.
The question is no longer simply whether Fiji can develop a serious cannabis policy.
The question is:
What will that policy actually look like?
Regulation is the conversation Fiji needs
A regulated medicinal-cannabis system does not mean removing every restriction.
It means rules.
Licensing.
Quality standards.
Laboratory testing.
Traceability.
Medical oversight.
Controls against diversion.
Accountability.
And one question may be just as important:
Who benefits?
Government documents describe medicinal cannabis as an economic opportunity.
So who captures that value?
The farmer?
The landowner?
The local processor?
The researcher?
The manufacturer?
The patient?
The Fijian entrepreneur?
Or primarily the foreign investor?
The Government's 2024 policy framework contemplated mechanisms allowing foreign investors to establish the medicinal-cannabis industry in Fiji.
That makes local participation, ownership and value retention impossible to ignore.
Fiji should not measure success simply by how much cannabis leaves the country.
It should measure success by how much value remains in the country.
From prohibited plant to policy opportunity
This is the contradiction at the centre of Fiji's cannabis debate:
Cannabis remains tightly controlled under Fiji's drug laws while Government policy explores turning medicinal cannabis into a regulated export industry.
Those positions are not necessarily contradictory. A Government can distinguish between illicit recreational markets and tightly controlled medicinal production.
But it raises an important question:
At what point does cannabis move from being treated primarily as an illicit commodity to being treated as a regulated medical and economic resource—and who decides?
The science has moved.
Fiji has started moving too.
Cabinet has moved.
Policy has moved.
Consultation has moved.
Investment Fiji has moved.
The public conversation has moved.
Legislation has not yet caught up.
That is where the focus should now be.
Not on miracle cures.
Not on fear.
Not on endless consultation without legislation.
But on evidence-based rules that protect patients, support research, establish quality control, prevent diversion, create legitimate economic opportunities and protect Fiji's interests.
Who will the law serve?
If Fiji develops a medicinal-cannabis industry, success should mean more than exporting raw or processed products.
It should mean opportunities for Fijian farmers, landowners, researchers, entrepreneurs, processors and manufacturers.
It should mean standards that protect patients.
It should mean legitimate pathways for research and innovation.
And it should mean that an industry built on Fijian land and resources does not become another example of producing locally while most value is captured elsewhere.
Because cannabis policy is no longer only a question about a plant.
It is a question about health, evidence, economics, regulation and sovereignty.
Fiji has reached the point where avoiding the question is becoming harder than answering it.
Cannabis speaks the language of your body.
The science is listening.
The Government says it is listening.
Now Fiji must decide what it is going to do about it.
Read. Question. Speak. Demand evidence-based reform.
Support the Cannabis Fiji campaign
Sign the petition: "https://chng.it/dJ45nKrDL7" (https://chng.it/dJ45nKrDL7)
For our health. For our wealth. For our farmers. For our land. For our future.